In patients with locally advanced or metastatic colorectal cancer, what are the benefits and harms of palliative chemotherapy?
S t u d y s e l e c t i o n
Studies in any language were selected if they were randomized controlled trials (RCTs) that compared palliative chemotherapy with supportive care alone in patients with advanced or metastatic colorectal cancer.
D a t a e x t r a c t i o n
The quality of studies was assessed by using the Jadad scale. Authors were contacted for individual patient data (baseline patient characteristics, allocated treatment group, date of randomization, tumor response, survival and progression status, and date of death or last follow-up). 2 reviewers extracted data from published studies, and meta-analysis was done by using both published data and individual patient data.
M a i n r e s u l t s 13 RCTs (1365 patients) met the selection criteria. Individual patient data were obtained for 7 RCTs (866 patients). Metaanalysis of published data showed that palliative chemotherapy (5-fluorouracil [5-FU], alone or in combination; fluoridine; irinotecan; or tauromustine) led to a reduction in death and progression at 12 months (Table) . Statistically significant heterogeneity existed among these RCTs. Studies with individual patient data were not heterogeneous; they also showed a reduction in death (7 RCTs; number needed to treat [NNT] 6, 95% CI 4 to 11) and progression (3 RCTs, NNT 4) at 12 months. The evidence for toxicity, quality of life, and symptom control was inconclusive because of inconsistent reporting and use of poor-quality methods.
C o n c l u s i o n s
In patients with locally advanced or metastatic colorectal cancer, palliative chemotherapy reduces death and progression at 12 months. The evidence on toxicity, symptom control, and quality of life is inconclusive. 
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C o m m e n t a r y
This well-conducted meta-analysis by the Colorectal Meta-analysis Collaboration supports the view that palliative chemotherapy is beneficial in treating colorectal cancer. Progression-free survival is prolonged, and deaths are reduced at 12 months. The benefits are substantial and clinically important. When studies with individual patient data are analyzed, relative risk reductions of 35% in deaths and 49% in progression at 12 months are shown. This finding translates into a 16% absolute difference in survival and a 25% increase in progression-free survival (increases of 3.7 mo in median survival and 6 mo in median progression-free survival). This benefit is probably underestimated. An unknown proportion of patients randomly allocated to supportive care received delayed chemotherapy, and 3 trials allowed chemotherapy at the onset.
The issue is not whether to treat but when and how it is best to treat. Other potential modalities that either improve outcome or decrease toxicity include the use of continuous-infusion 5-FU (1), oral 5-FU (2), and combination chemotherapy (3). Future studies that incorporate measures of quality of life will better define the role of palliative chemotherapy in colorectal cancer.
